HomeCompareCIMDF vs ABBV

CIMDF vs ABBV: Dividend Comparison 2026

CIMDF yields 5.79% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIMDF wins by $14251.79M in total portfolio value
10 years
CIMDF
CIMDF
● Live price
5.79%
Share price
$2.00
Annual div
$0.12
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14251.89M
Annual income
$13,793,912,290.49
Full CIMDF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CIMDF vs ABBV

📍 CIMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIMDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIMDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIMDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIMDF
Annual income on $10K today (after 15% tax)
$491.81/yr
After 10yr DRIP, annual income (after tax)
$11,724,825,446.92/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CIMDF beats the other by $11,724,804,390.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIMDF + ABBV for your $10,000?

CIMDF: 50%ABBV: 50%
100% ABBV50/50100% CIMDF
Portfolio after 10yr
$7126.00M
Annual income
$6,896,968,531.13/yr
Blended yield
96.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CIMDF
No analyst data
Altman Z
-0.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIMDF buys
0
ABBV buys
0
No recent congressional trades found for CIMDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIMDFABBV
Forward yield5.79%3.06%
Annual dividend / share$0.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$14251.89M$102.3K
Annual income after 10y$13,793,912,290.49$24,771.77
Total dividends collected$14220.09M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CIMDF vs ABBV ($10,000, DRIP)

YearCIMDF PortfolioCIMDF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,857$1,157.20$11,550$430.00+$307.00CIMDF
2$15,252$2,564.70$13,472$627.96+$1.8KCIMDF
3$22,486$6,166.30$15,906$926.08+$6.6KCIMDF
4$41,052$16,992.46$19,071$1,382.55+$22.0KCIMDF
5$101,913$57,987.04$23,302$2,095.81+$78.6KCIMDF
6$378,119$269,072.40$29,150$3,237.93+$349.0KCIMDF
7$2,270,600$1,866,012.72$37,536$5,121.41+$2.23MCIMDF
8$23,374,171$20,944,628.33$50,079$8,338.38+$23.32MCIMDF
9$428,019,025$403,008,662.31$69,753$14,065.80+$427.95MCIMDF
10$14,251,892,647$13,793,912,290.49$102,337$24,771.77+$14251.79MCIMDF

CIMDF vs ABBV: Complete Analysis 2026

CIMDFStock

CIMB Group Holdings Berhad provides various banking products and services in Malaysia and internationally. The company's Consumer Banking segment offers conventional and Islamic financial products and services, such as residential and non-residential property loans, secured personal loans, motor vehicle financing, credit cards, unsecured personal financing, wealth management, bancassurance, remittance and foreign exchange, deposits, and internet banking services to individual customers. Its Commercial Banking segment provides banking credit facilities, trade financing, cash management, remittance and foreign exchange, and general deposit products, as well as an online business banking platform to small and medium-scale enterprises, and mid-sized corporations. The company's Wholesale Banking segment offers client coverage marketing and delivering solutions; financial advisory services on issuance of equity and equity-linked products, debt restructuring, initial public offerings, secondary offerings, and general corporate advisory; conventional and Islamic funding solutions covering trade, working capital line, capital expenditure, leveraging, merger and acquisition, leveraged, and project financing products; and holistic funding solutions, including cash management, trade finance, foreign exchange, custody and corporate loans, derivatives, structured products, and debt capital. This segment also engages in the treasury activities and services comprising foreign exchange, money market, derivatives, and capital market trading instruments; transaction banking and broking services; and wealth management solutions, as well as investment, securities financing, and trust services. It operates through 630 retail branches and 7,652 self-service customer access points in 15 countries. The company was founded in 1924 and is headquartered in Kuala Lumpur, Malaysia.

Full CIMDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CIMDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIMDF vs SCHDCIMDF vs JEPICIMDF vs OCIMDF vs KOCIMDF vs MAINCIMDF vs JNJCIMDF vs MRKCIMDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.